Skip to main content
Mazin Abdelghany on Muck Rack

Mazin Abdelghany

As seen in: Wiley Online Library, PLOS ONE, Genome Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mazin

Contact Mazin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Thorough QT/QTc Clinical Study to Evaluate the Effect of Remdesivir on Cardiac Repolarization in Healthy Participants

|
By Chi-Chi Peng, Ran Duan, Mazin Abdelghany
| Wiley Online Library Verified
1 Introduction QT interval prolongation (i.e., delay in cardiac repolarization) [1] associated with drug administration may result in the development of a delay in ventricular repolarization, which is associated with a risk of torsade de pointes [2]; therefore, assessment of corrected QT interval (QTc) prolongation has become an important consideration in drug development [3].
Open in Who Shared Issue with article?

Bayesian reanalysis of early remdesivir for the treatment of COVID-19 in outpatients with high risk of progression to severe disease

|
By Mazin Abdelghany, Fang Yu, Stephen I. Rennard
| PLOS ONE
Loading metrics Open Access Peer-reviewed Research Article Citation: Abdelghany M, Yu F, Rennard S, Gwon Y (2026) Bayesian reanalysis of early remdesivir for the treatment of COVID-19 in outpatients with high risk of progression to severe disease. PLoS One 21(4): e0346878.
Open in Who Shared Issue with article?

Pharmacokinetics of SARS‐CoV‐2 RNA Polymerase Inhibitor Remdesivir in Participants With Moderate and Severe Hepatic Impairment

|
By Sean Regan, Rita Humeniuk, Luzelena Caro, Mazin Abdelghany
| Wiley Online Library Verified
What is the current knowledge on the topic? ○ Remdesivir is an intravenous prodrug approved for the treatment of coronavirus disease 2019 (COVID-19). Remdesivir and its metabolite GS-704277 are eliminated primarily via the metabolizing enzymes carboxylesterase 1 and histidine triad nucleotide-binding protein 1, while the metabolite GS-441524 is eliminated renally.
Open in Who Shared Issue with article?
See all 4 articles